Employees: 129
Size Brainsway Ltd Sponsored ADR (BWAY) is a United States Health Care company (Medical Specialties) with a market value of $373M, the 2898th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.98 on 18 Nov 2026.
Performance Over six months the shares fell 41.2%, against -15.0% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 32.5% over the last twelve months (peer median +7.1%); the operating margin is 13.6% (peer median 7.9%).
Valuation It trades at 20.3× forward earnings against a peer median of 15.8× (4th most expensive of 11).
Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 15.7 points above its cost of capital (11.8% WACC).
Short interest Short interest is 0.5% of the free float (30 Oct 2026).
Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $65.5M | $52.6M | $41.2M | $31.7M | $27.1M |
| Revenue growth | — | +28% | +30% | +17% | — |
| Gross profit | $49.8M | $39.0M | $30.1M | $23.0M | $20.4M |
| EBITDA | $10.7M | $5.91M | $3.18M | -$3.58M | -$10.3M |
| Net income | $10.1M | $7.64M | $2.93M | -$4.19M | -$13.3M |
| Free cash flow | $12.9M | $15.3M | $6.53M | -$1.10M | n/a |
| Capital expenditure | -$517,592 | $3.02M | $4.79M | $2.40M | $20,918 |
| Total debt | $6.88M | $6.82M | $5.62M | $471,003 | $488,006 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BWAY | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -25.4% | -10.9% | 2nd lowest of 21 |
| 6-month return | -41.2% | -15.0% | 3rd lowest of 20 |
| Distance from 52-week high | -48.4% | -43.6% | 5th lowest of 21 |
| Revenue growth (TTM) | +32.5% | +7.1% | 3rd highest of 21 |
| Operating margin | 13.6% | 7.9% | 10th highest of 21 |
| Forward P/E | 20.3× | 15.8× | 4th most expensive of 11 |
| Growth the price implies (Req g, 7 yrs) | 24.9% | -6.3% | 2nd most demanding of 14 |
| Growth delivered (Del g) | +18.8% | +4.4% | 3rd highest of 14 |
| Hurdle (Req g minus delivered) | +6.1 pp | -2.9 pp | 4th most demanding of 14 |
| ROIC minus cost of capital | +15.7 pp | +4.7 pp | 5th highest of 20 |
| EV / EBITDA | 29.6× | 7.9× | 2nd most expensive of 11 |
| Net debt / EBITDA | -5.3× | -1.2× | 3rd least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Brainsway Ltd Sponsored ADR BWAY | United States | $373M | -41% | +32% | 14% | 20.3× | 24.9% | +18.8% |
| Guangdong Transtek Medical Electronics 300562.SZ | China | $373M | -15% | +7% | 11% | 25.3× | -4.2% | -6.0% |
| ACRO Biomedical 6748.TWO | Taiwan | $377M | +158% | +45% | -178% | n/a | n/a | n/a |
| Medcaptain Medical Technology 2041.HK | Hong Kong | $378M | n/a | +19% | 2% | n/a | 17.1% | +18.1% |
| Shanghai General Healthy Information & Technology 605186.SS | China | $379M | -26% | -11% | 5% | 37.2× | n/a | n/a |
| CapsoVision CV | United States | $366M | +5% | +15% | -213% | n/a | n/a | n/a |
| InBody 041830.KS | South Korea | $380M | -13% | +22% | 22% | 11.3× | -10.3% | +16.9% |
| Stratec SBS.DE | Germany | $365M | +63% | -6% | 4% | 18.2× | 19.1% | +0.1% |
| Star Sports Medicine 1609.HK | Hong Kong | $364M | -73% | +23% | 37% | n/a | -13.1% | +36.8% |
| Beijing Succeeder Technology 688338.SS | China | $362M | -18% | -4% | 31% | 16.4× | 5.7% | +3.4% |
| Taidoc Technology 4736.TW | Taiwan | $387M | 0% | 0% | 19% | n/a | -9.5% | -6.6% |
| Shanghai Kehua Bio-Engineering 002022.SZ | China | $389M | -14% | +7% | -40% | n/a | n/a | n/a |
| Cerus CERS | United States | $392M | -28% | +14% | -12% | n/a | n/a | n/a |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $354M | -23% | -8% | 17% | 36.0× | 18.4% | +4.4% |
| SEERS 458870.KS | South Korea | $392M | -70% | +174% | 37% | 15.2× | -6.3% | +247.0% |
| OrbusNeich Medical 6929.HK | Hong Kong | $394M | -15% | +16% | 23% | 8.4× | -17.6% | +15.4% |
| IVF HARTMANN VBSN.SW | Switzerland | $352M | -2% | +7% | 14% | n/a | -12.7% | -1.3% |
| 908 Devices MASS | United States | $396M | +36% | +14% | -33% | n/a | 41.7% | +15.9% |
| Guanhao Biotech 300238.SZ | China | $397M | -26% | -12% | 3% | n/a | n/a | n/a |
| Embecta EMBC | United States | $345M | +99% | -8% | 26% | 3.8× | -19.9% | -0.1% |
| Shanghai Titan Scientific 688133.SS | China | $403M | -26% | +1% | -6% | 8.4× | n/a | n/a |